{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T11:01:23Z","timestamp":1776078083278,"version":"3.50.1"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2024,8,9]],"date-time":"2024-08-09T00:00:00Z","timestamp":1723161600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,8,9]],"date-time":"2024-08-09T00:00:00Z","timestamp":1723161600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rheumatol Ther"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1007\/s40744-024-00707-9","type":"journal-article","created":{"date-parts":[[2024,8,9]],"date-time":"2024-08-09T10:02:47Z","timestamp":1723197767000},"page":"1303-1319","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Efficacy and Safety of Biologics in Polymyalgia Rheumatica: A Retrospective Study"],"prefix":"10.1007","volume":"11","author":[{"given":"Naoaki","family":"Ohkubo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yusuke","family":"Miyazaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shingo","family":"Nakayamada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shunsuke","family":"Fukuyo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshino","family":"Inoue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yurie","family":"Satoh-Kanda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroaki","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuyuki","family":"Todoroki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroko","family":"Miyata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsushi","family":"Nagayasu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masashi","family":"Funada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroki","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hidenori","family":"Sakai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shumpei","family":"Kosaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satsuki","family":"Matsunaga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yukiko","family":"Tomoyose","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hirotsugu","family":"Nohara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0807-7139","authenticated-orcid":false,"given":"Yoshiya","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,8,9]]},"reference":[{"issue":"10","key":"707_CR1","doi-asserted-by":"publisher","first-page":"1799","DOI":"10.1136\/annrheumdis-2015-207492","volume":"74","author":"C Dejaco","year":"2015","unstructured":"Dejaco C, Singh YP, Perel P, et al. 2015 Recommendations for the management of polymyalgia rheumatica: a European League Against Rheumatism\/American College of Rheumatology collaborative initiative. Ann Rheum Dis. 2015;74(10):1799\u2013807.","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"707_CR2","doi-asserted-by":"publisher","first-page":"493","DOI":"10.7326\/0003-4819-141-7-200410050-00005","volume":"141","author":"R Caporali","year":"2004","unstructured":"Caporali R, Cimmino MA, Ferraccioli G, et al. Prednisone plus methotrexate for polymyalgia rheumatica: a randomized, double-blind, placebo-controlled trial. Ann Intern Med. 2004;141(7):493\u2013500.","journal-title":"Ann Intern Med"},{"issue":"1","key":"707_CR3","first-page":"65","volume":"32","author":"HM Kremers","year":"2005","unstructured":"Kremers HM, Reinalda MS, Crowson CS, Zinsmeister AR, Hunder GG, Gabriel SE. Relapse in a population-based cohort of patients with polymyalgia rheumatica. J Rheumatol. 2005;32(1):65\u201373.","journal-title":"J Rheumatol"},{"issue":"1","key":"707_CR4","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1002\/art.20901","volume":"53","author":"C Salvarani","year":"2005","unstructured":"Salvarani C, Cantini F, Niccoli L, et al. Acute-phase reactants and the risk of relapse\/recurrence in polymyalgia rheumatica: a prospective follow-up study. Arthritis Rheum. 2005;53(1):33\u20138.","journal-title":"Arthritis Rheum"},{"issue":"7","key":"707_CR5","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1002\/art.41752","volume":"73","author":"L Fraenkel","year":"2021","unstructured":"Fraenkel L, Bathon JM, England BR, et al. 2021 American College of Rheumatology Guideline for the treatment of rheumatoid arthritis. Arthritis Rheumatol. 2021;73(7):1108\u201323.","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"707_CR6","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1136\/ard-2022-223356","volume":"82","author":"JS Smolen","year":"2023","unstructured":"Smolen JS, Landew\u00e9 RBM, Bergstra SA, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Ann Rheum Dis. 2023;82(1):3\u201318.","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"707_CR7","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1136\/ard.55.4.218","volume":"55","author":"MJ Van der Veen","year":"1996","unstructured":"Van der Veen MJ, Dinant HJ, van Booma-Frankfort C, van Albada-Kuipers GA, Bijlsma JW. Can methotrexate be used as a steroid sparing agent in the treatment of polymyalgia rheumatica and giant cell arteritis? Ann Rheum Dis. 1996;55(4):218\u201323.","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"707_CR8","first-page":"624","volume":"23","author":"G Ferraccioli","year":"1996","unstructured":"Ferraccioli G, Salaffi F, De Vita S, Casatta L, Bartoli E. Methotrexate in polymyalgia rheumatica: preliminary results of an open, randomized study. J Rheumatol. 1996;23(4):624\u20138.","journal-title":"J Rheumatol"},{"issue":"9","key":"707_CR9","doi-asserted-by":"publisher","first-page":"631","DOI":"10.7326\/0003-4819-146-9-200705010-00005","volume":"146","author":"C Salvarani","year":"2007","unstructured":"Salvarani C, Macchioni PL, Manzini C, et al. Infliximab plus prednisone or placebo plus prednisone for the initial treatment of polymyalgia rheumatica: a randomized trial. Ann Intern Med. 2007;146(9):631\u20139.","journal-title":"Ann Intern Med"},{"issue":"5","key":"707_CR10","doi-asserted-by":"publisher","first-page":"R176","DOI":"10.1186\/ar3140","volume":"12","author":"F Kreiner","year":"2010","unstructured":"Kreiner F, Galbo H. Effect of etanercept in polymyalgia rheumatica: a randomized controlled trial. Arthritis Res Ther. 2010;12(5):R176.","journal-title":"Arthritis Res Ther"},{"issue":"4","key":"707_CR11","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1056\/NEJMoa1613849","volume":"377","author":"JH Stone","year":"2017","unstructured":"Stone JH, Tuckwell K, Dimonaco S, et al. Trial of tocilizumab in giant-cell arteritis. N Engl J Med. 2017;377(4):317\u201328.","journal-title":"N Engl J Med"},{"issue":"4","key":"707_CR12","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1002\/art.40044","volume":"69","author":"CA Langford","year":"2017","unstructured":"Langford CA, Cuthbertson D, Ytterberg SR, et al. A randomized, double-blind trial of abatacept (CTLA-4Ig) for the treatment of giant cell arteritis. Arthritis Rheumatol. 2017;69(4):837\u201345.","journal-title":"Arthritis Rheumatol"},{"issue":"2","key":"707_CR13","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1016\/j.semarthrit.2021.03.006","volume":"51","author":"R Spiera","year":"2021","unstructured":"Spiera R, Unizony SH, Bao M, et al. Tocilizumab vs placebo for the treatment of giant cell arteritis with polymyalgia rheumatica symptoms, cranial symptoms, or both in a randomized trial. Semin Arthritis Rheum. 2021;51(2):469\u201376.","journal-title":"Semin Arthritis Rheum"},{"issue":"8","key":"707_CR14","volume":"14","author":"M Farinango","year":"2022","unstructured":"Farinango M, Ansary A, Dakka A, et al. Is tocilizumab effective and safe in polymyalgia rheumatica and giant-cell arteritis with polymyalgia rheumatica? Cureus. 2022;14(8):e27606.","journal-title":"Cureus"},{"key":"707_CR15","doi-asserted-by":"publisher","first-page":"484","DOI":"10.7326\/0003-4819-121-7-199410010-00003","volume":"121","author":"CM Weyand","year":"1994","unstructured":"Weyand CM, Hicok KC, Hunder GG, et al. Tissue cytokine patterns in patients with polymyalgia rheumatica and giant cell arteritis. Ann Intern Med. 1994;121:484\u201391.","journal-title":"Ann Intern Med"},{"issue":"2","key":"707_CR16","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2016-000305","volume":"2","author":"\u00c9 Toussirot","year":"2016","unstructured":"Toussirot \u00c9, R\u00e9gent A, Devauchelle-Pensec V, Saraux A, Pu\u00e9chal X. Interleukin-6: a promising target for the treatment of polymyalgia rheumatica or giant cell arteritis? RMD Open. 2016;2(2):e000305.","journal-title":"RMD Open"},{"issue":"11","key":"707_CR17","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1001\/jama.2022.15459","volume":"328","author":"V Devauchelle-Pensec","year":"2022","unstructured":"Devauchelle-Pensec V, Carvajal-Alegria G, Dernis E, et al. Effect of tocilizumab on disease activity in patients with active polymyalgia rheumatica receiving glucocorticoid therapy: a randomized clinical trial. JAMA. 2022;328(11):1053\u201362.","journal-title":"JAMA"},{"issue":"6","key":"707_CR18","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1136\/annrheumdis-2021-221126","volume":"81","author":"M Bonelli","year":"2022","unstructured":"Bonelli M, Radner H, Kerschbaumer A, et al. Tocilizumab in patients with new onset polymyalgia rheumatica (PMR-SPARE): a phase\u00a02\/3 randomized controlled trial. Ann Rheum Dis. 2022;81(6):838\u201344.","journal-title":"Ann Rheum Dis"},{"issue":"14","key":"707_CR19","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1056\/NEJMoa2303452","volume":"389","author":"RF Spiera","year":"2023","unstructured":"Spiera RF, Unizony S, Warrington KJ, et al. Sarilumab for relapse of polymyalgia rheumatica during glucocorticoid taper. N Engl J Med. 2023;389(14):1263\u201372.","journal-title":"N Engl J Med"},{"issue":"12","key":"707_CR20","doi-asserted-by":"publisher","first-page":"e728","DOI":"10.1016\/S2665-9913(23)00246-1","volume":"5","author":"A Saraux","year":"2023","unstructured":"Saraux A, Le Henaff C, Dernis E, et al. Abatacept in early polymyalgia rheumatica (ALORS): a proof-of-concept, randomised, placebo-controlled, parallel-group trial. Lancet Rheumatol. 2023;5(12):e728\u2013735.","journal-title":"Lancet Rheumatol"},{"issue":"3","key":"707_CR21","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/j.semarthrit.2019.12.005","volume":"50","author":"M Akiyama","year":"2020","unstructured":"Akiyama M, Kaneko Y, Takeuchi T. Tocilizumab in isolated polymyalgia rheumatica: a systematic literature review. Semin Arthritis Rheum. 2020;50(3):521\u20135.","journal-title":"Semin Arthritis Rheum"},{"issue":"8","key":"707_CR22","doi-asserted-by":"publisher","first-page":"1506","DOI":"10.1136\/annrheumdis-2015-208742","volume":"75","author":"V Devauchelle-Pensec","year":"2016","unstructured":"Devauchelle-Pensec V, Berthelot JM, Cornec D, et al. Efficacy of first-line tocilizumab therapy in early polymyalgia rheumatica: a prospective longitudinal study. Ann Rheum Dis. 2016;75(8):1506\u201310.","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"707_CR23","doi-asserted-by":"publisher","first-page":"2550","DOI":"10.1002\/art.39740","volume":"68","author":"L Lally","year":"2016","unstructured":"Lally L, Forbess L, Hatzis C, Spiera R. Brief report: a prospective open-label phase\u00a0IIa trial of tocilizumab in the treatment of polymyalgia rheumatica. Arthritis Rheumatol. 2016;68(10):2550\u20134.","journal-title":"Arthritis Rheumatol"},{"issue":"12","key":"707_CR24","doi-asserted-by":"publisher","first-page":"2151","DOI":"10.1111\/1756-185X.13723","volume":"22","author":"K Chino","year":"2019","unstructured":"Chino K, Kondo T, Sakai R, et al. Tocilizumab monotherapy for polymyalgia rheumatica: a prospective, single-center, open-label study. Int J Rheum Dis. 2019;22(12):2151\u20137.","journal-title":"Int J Rheum Dis"},{"issue":"1","key":"707_CR25","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s13075-020-02377-8","volume":"23","author":"S Unizony","year":"2021","unstructured":"Unizony S, McCulley TJ, Spiera R, et al. Clinical outcomes of patients with giant cell arteritis treated with tocilizumab in real-world clinical practice: decreased incidence of new visual manifestations. Arthritis Res Ther. 2021;23(1):8.","journal-title":"Arthritis Res Ther"},{"issue":"13","key":"707_CR26","doi-asserted-by":"publisher","first-page":"2948","DOI":"10.3390\/jcm10132948","volume":"10","author":"K Izumi","year":"2021","unstructured":"Izumi K, Murata O, Higashida-Konishi M, Kaneko Y, Oshima H, Takeuchi T. Steroid-sparing effect of tocilizumab and methotrexate in patients with polymyalgia rheumatica: a retrospective cohort study. J Clin Med. 2021;10(13):2948.","journal-title":"J Clin Med"},{"issue":"11","key":"707_CR27","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1016\/S2665-9913(21)00245-9","volume":"3","author":"DE Marsman","year":"2021","unstructured":"Marsman DE, Den Broeder N, Van den Hoogen FHJ, et al. Efficacy of rituximab in patients with polymyalgia rheumatica: a double-blind, randomized, placebo-controlled, proof-of-concept trial. Lancet Rheumatol. 2021;3(11):758\u201366.","journal-title":"Lancet Rheumatol"},{"issue":"4","key":"707_CR28","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1093\/rheumatology\/kex477","volume":"57","author":"V Devauchelle-Pensec","year":"2018","unstructured":"Devauchelle-Pensec V, Saraux L, Berthelot JM, et al. Assessing polymyalgia rheumatica activity when C-reactive protein is unavailable or uninterpretable. Rheumatol (Oxf Engl). 2018;57(4):666\u201370.","journal-title":"Rheumatol (Oxf Engl)"},{"issue":"5","key":"707_CR29","first-page":"S141","volume":"22","author":"JJ Cush","year":"2004","unstructured":"Cush JJ. Unusual toxicities with TNF inhibition: heart failure and drug-induced lupus. Clin Exp Rheumatol. 2004;22(5):S141\u20137.","journal-title":"Clin Exp Rheumatol"},{"issue":"3","key":"707_CR30","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1016\/j.clinimag.2015.11.013","volume":"40","author":"S Kinoshita","year":"2016","unstructured":"Kinoshita S, Aoki T, Takahashi H, et al. Thin-section chest CT findings in polymyalgia rheumatica: a comparison between with and without rheumatoid arthritis. Clin Imaging. 2016;40(3):382\u20135.","journal-title":"Clin Imaging"},{"issue":"1","key":"707_CR31","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1093\/rheumatology\/kep303a","volume":"49","author":"B Dasgupta","year":"2010","unstructured":"Dasgupta B, Borg FA, Hassan N, et al. BSR and BHPR guidelines for the management of polymyalgia rheumatica. Rheumatol (Oxf Engl). 2010;49(1):186\u201390.","journal-title":"Rheumatol (Oxf Engl)"}],"container-title":["Rheumatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40744-024-00707-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40744-024-00707-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40744-024-00707-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,24]],"date-time":"2024-09-24T06:07:45Z","timestamp":1727158065000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40744-024-00707-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,9]]},"references-count":31,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["707"],"URL":"https:\/\/doi.org\/10.1007\/s40744-024-00707-9","relation":{},"ISSN":["2198-6576","2198-6584"],"issn-type":[{"value":"2198-6576","type":"print"},{"value":"2198-6584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,9]]},"assertion":[{"value":"7 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 July 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 August 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Yoshiya Tanaka has received speaking fees and\/or honoraria from Eli Lilly, AstraZeneca, Abbvie, Gilead, Chugai, Behringer Ingelheim, GlaxoSmithKline, Eisai, Taisho, Bristol-Myers, Pfizer, and Taiho, and received research grants from Mitsubishi-Tanabe, Eisai, Chugai, and Taisho. Shingo Nakayamada has received consulting fees, speaking fees, and\/or honoraria from Bristol-Myers, AstraZeneca, Pfizer, GlaxoSmithKline, Astellas, Asahi-kasei, Sanofi, Abbvie, Eisai, Chugai, Gilead, and Boehringer Ingelheim, and has received research grants from Mitsubishi-Tanabe. The authors declare no conflicts of interest. Yusuke Miyazaki has received consulting fees, speaking fees, and\/or honoraria from Eli Lilly and has received research grants from GlaxoSmithKline. Yoshiya Tanaka is an Editorial Board member of <i>Rheumatology and Therapy<\/i>. Yoshiya Tanaka was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions. Naoaki Ohkubo, Shunsuke Fukuyo, Yoshino Inoue, Yurie Satoh-Kanda, Hiroaki Tanaka, Yasuyuki Todoroki, Hiroko Miyata, Atsushi Nagayasu, Masashi Funada, Hiroki Kobayashi, Hidenori Sakai, Shumpei Kosaka, Satsuki Matsunaga, Yukiko Tomoyose, Hirotsugu Nohara have nothing to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study complied with the Declaration of Helsinki and the research protocol was approved by the Ethics Committee of the School of Medicine, University of Occupational and Environmental Health, Japan (UOEHCRB21-068). In addition, informed consent was obtained appropriately by the Ethical Guidelines for Medical and Health Research Involving Human Subjects published by the Ministry of Health, Labor, and Welfare in April 2015.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}